Table of contents

Metabolic dysfunction-associated steatotic liver disease

What's new

Updated 2023 AGA and 2023 ESPEN/UEG guidelines for the diagnosis and management of non-alcoholic fatty liver disease.


Key sources

The following summarized guidelines for the evaluation and management of metabolic dysfunction-associated steatotic liver disease are prepared by our editorial team based on guidelines from the American Association for the Study of Liver Diseases (AASLD 2024,2023), the American Diabetes Association (ADA 2024), the World Federation for Ultrasound in Medicine and Biology (WFUMB 2024), the American Gastroenterological Association (AGA 2023,2022,2021), the ...
Show more

Screening and diagnosis

Indications for screening, adult patients
As per AASLD 2023 guidelines:
Do not obtain general population-based screening for MASLD.
Screen for advanced fibrosis in patients at high risk, such as patients with T2DM, medically complicated obesity, family history of cirrhosis, or more than mild alcohol consumption.
Create free account

More topics in this section

  • Indications for screening (pediatric patients)

  • Indications for screening (family relatives)

Classification and risk stratification

Noninvasive assessment of fibrosis: as per AASLD 2024 guidelines, obtain simple blood-based noninvasive liver disease assessment tests, such as FIB-4, to detect advanced fibrosis in adult patients with MASLD undergoing fibrosis staging.
Show 3 more

Diagnostic investigations

Initial evaluation: as per AASLD 2023 guidelines, do not obtain an ultrasound to identify hepatic steatosis due to low sensitivity across the MASLD spectrum, although standard ultrasound can detect hepatic steatosis. Consider using a controlled attenuation parameter as a point-of-care technique to identify steatosis.
Show 3 more

More topics in this section

  • Liver elastography

  • MRS

  • Serum biomarkers

  • Genetic testing

  • Nutritional assessment

  • Screening for comorbidities

Diagnostic procedures

Liver biopsy: as per AGA 2023 guidelines, consider performing a liver biopsy in patients with indeterminate or discordant noninvasive test results, conflict with other clinical, laboratory, or radiologic findings, or suspected alternative etiologies for liver disease.

Medical management

General principles: as per AASLD 2023 guidelines, recognize that there are currently no FDA-approved medications for the treatment of MASLD Consider initiating drugs approved to treat associated comorbidities with potential benefit in MASLD in the appropriate clinical setting.

More topics in this section

  • Glucose-lowering agents

  • Bile acids

  • Other agents

  • Management of comorbidities

Nonpharmacologic interventions

Dietary modifications: as per AASLD 2023 guidelines, advise a diet leading to a caloric deficit in patients with MASLD with overweight or obesity. Encourage diets with limited carbohydrates and saturated fat and enriched with high fiber and unsaturated fats (such as the Mediterranean diet) when possible due to their additional cardiovascular benefits.

More topics in this section

  • Weight loss

  • Protein intake

  • Physical activity

  • Smoking cessation

  • Alcohol restriction

  • Omega-3 fatty acids

  • Vitamin E

  • Probiotics

Therapeutic procedures

Intragastric balloon: as per ESPEN/UEG 2023 guidelines, consider placing a transient endoscopic gastric balloon for nonoperative management in selected patients with MASH without portal hypertension.

Surgical interventions

Bariatric surgery: as per AASLD 2023 guidelines, consider performing bariatric surgery as a therapeutic option in patients meeting the criteria for metabolic weight loss surgery, as it effectively resolves MASLD or MASH in most patients without cirrhosis and reduces mortality from CVD and malignancy.

More topics in this section

  • Liver transplantation (indications)

  • Liver transplantation (pre-transplant evaluation)

  • Liver transplantation (pre-transplant management)

Specific circumstances

Lean patients, screening
As per AGA 2022 guidelines:
Do not obtain routine screening for MASLD in lean persons in the general population.
Consider obtaining screening for MASLD in > 40 years old patients with T2DM.

More topics in this section

  • Lean patients (diagnosis)

  • Lean patients (differential diagnosis)

  • Lean patients (risk stratification)

  • Lean patients (noninvasive assessment of fibrosis)

  • Lean patients (imaging)

  • Lean patients (liver biopsy)

  • Lean patients (genetic testing)

  • Lean patients (lifestyle modifications)

  • Lean patients (vitamin E)

  • Lean patients (glucose-lowering agents)

  • Lean patients (serial clinical assessment)

  • Lean patients (surveillance for HCC)

  • Pediatric patients (screening)

  • Pediatric patients (diagnosis)

  • Pediatric patients (management)

  • Pediatric patients (follow-up)

  • Pregnant patients (pre-conception care)

  • Pregnant patients (management during pregnancy)

  • Pregnant patients (breastfeeding)

Follow-up and surveillance

Indications for referral: as per AASLD 2023 guidelines, refer patients with suspected advanced MASH or discordant noninvasive tests to a specialist for evaluation, management, and/or further diagnostic evaluation.

More topics in this section

  • Serial clinical assessment

  • Serial laboratory and imaging assessment

  • Surveillance for HCC